The impact of anti-drug antibodies on drug concentrations and clinical outcomes in rheumatoid arthritis patients treated with adalimumab, etanercept, or infliximab: Results from a multinational, real-world clinical practice, non-interventional study

OBJECTIVE: To assess the incidence of anti-drug antibodies (ADA) in patients with rheumatoid arthritis (RA) treated with the TNF inhibitors etanercept (ETN), adalimumab (ADL), or infliximab (IFX), and determine the potential relationship with trough drug concentration, efficacy, and patient-reported...

Descripción completa

Detalles Bibliográficos
Autores principales: Moots, Robert J., Xavier, Ricardo M., Mok, Chi Chiu, Rahman, Mahboob U., Tsai, Wen-Chan, Al-Maini, Mustafa H., Pavelka, Karel, Mahgoub, Ehab, Kotak, Sameer, Korth-Bradley, Joan, Pedersen, Ron, Mele, Linda, Shen, Qi, Vlahos, Bonnie
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Public Library of Science 2017
Materias:
Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5407581/
https://www.ncbi.nlm.nih.gov/pubmed/28448562
http://dx.doi.org/10.1371/journal.pone.0175207

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5407581/
https://www.ncbi.nlm.nih.gov/pubmed/28448562
http://dx.doi.org/10.1371/journal.pone.0175207

Ejemplares similares